A US-listed pharmaceutical and medical technology group with an Indian arm in Mumbai that hires across sales, R&D, data and HR.
jnj.comCEO
Joaquin Duato, Chairman and Chief Executive Officer
CFO
Joseph J. Wolk, Executive Vice President, Chief Financial Officer
Founded
1886 (India entity incorporated 5 September 1957)
Employees
138,200 globally (2025)
Industry
Pharmaceuticals, biotechnology and medical technology
Market Cap
$615.36 billion
Listed on
NYSE: JNJ (the India arm is an unlisted private subsidiary)
Headquarters
One Johnson & Johnson Plaza, New Brunswick, New Jersey, USA; India office at Higi House, LBS Marg, Mulund West, Mumbai 400080
Johnson & Johnson is an American healthcare company founded in 1886 and headquartered at Johnson and Johnson Plaza in New Brunswick, New Jersey. It trades on the New York Stock Exchange as JNJ and sits in both the Dow Jones Industrial Average and the S&P 500. The company employed about 138,200 people in 2025 and carries a market capitalisation of roughly $615 billion.
The business runs on two segments. Innovative Medicine covers prescription drugs across oncology, immunology, neuroscience, cardiovascular and pulmonary hypertension, and includes Janssen Pharmaceuticals, Actelion, Alza, Cilag and MorphoSys. MedTech covers surgery, orthopaedics, cardiovascular and vision, and includes DePuy Synthes, Ethicon, Abiomed, Johnson & Johnson Vision, Mentor and Synthes. Full-year 2025 sales came in at $94.19 billion, up 6.0%, with diluted EPS of $11.03, and the company has guided to more than $100 billion of revenue in 2026.
In India the group operates through Johnson & Johnson Private Limited, incorporated on 5 September 1957 with a registered office at Higi House, LBS Marg, Mulund West, Mumbai. That entity reported revenue of Rs 4,461.07 crore in FY2025, an 11% rise year on year, and is classified under medical consumables and supplies. Indian hiring spans Mumbai, Hyderabad, Pune, Bengaluru, Aurangabad and Kolkata, with about 74 openings listed on the India careers page.
Chairman and Chief Executive Officer
Executive Vice President, Chief Financial Officer
Executive Vice President, Worldwide Chairman, Innovative Medicine
Vice President, Investor Relations
Interview experience
8 out of 10 rated it favorable
Interview difficulty
Medium, 6 out of 10
Interview process length
About a month for most candidates
Practise real questions, get instant feedback on your answers and walk in ready.
Q: Tell us about the products you sold before, your former employer and your qualifications.
A: Walk through your last role in order: what you sold, who you sold it to and what results you can point to. Close with the qualification that maps to this job.
Q: What do you know about J&J products, and how would you detail them?
A: Pick one or two products from the segment you're interviewing for, explain the clinical problem they solve, then show your detailing structure rather than reciting a brochure.
Q: Introduce yourself, then explain ROI.
A: Keep the intro to about a minute and end it on why you're in this segment. Then define ROI plainly as return divided by investment, and prove it with a spend decision you actually made.
Q: Walk us through your distribution experience.
A: Cover the width of your channel, the stock and service metrics you owned, and one problem you fixed, such as stockouts, expiry or a non-performing distributor.
Practise real questions, get instant feedback on your answers and walk in ready.
Reported average, all levels
₹12,53,742/year
4 salaries reported Salaries submitted
Reported average, all levels
₹12,60,589/year
3 salaries reported Salaries submitted
Reported average, all levels
₹7,33,084/year
12 salaries reported Salaries submitted
Reported average, all levels
₹5,11,204/year
3 salaries reported Salaries submitted
Reported monthly average
₹44,975/month
3 salaries reported Salaries submitted
Reported monthly average
₹19,431/month
Compare your pay against live roles and see where you stand before you negotiate.
Tailor your resume to the role in minutes and get past the first screen.
July 15, 2026
J&J reports Q2 2026 sales of $25.3 billion and raises full-year guidance
Second-quarter reported sales rose 6.6% to $25.3 billion with adjusted EPS of $2.90. The company lifted full-year 2026 guidance to about $101.1 billion of sales, which would be its first year above $100 billion.
#Earnings #Pharma #MedTech
View postApril 30, 2026
Ryan Koors named Vice President, Investor Relations
J&J appointed Ryan Koors as VP of Investor Relations effective 7 May 2026, reporting to CFO Joseph J. Wolk. He succeeds Darren Snellgrove and has been with the company since 2002.
#Leadership #Appointment #InvestorRelations
View postApril 24, 2026
J&J agrees to acquire Atraverse Medical
The company signed a definitive agreement to buy Atraverse Medical, which makes the FDA-cleared HOTWIRE transseptal access system for left-heart procedures. Terms weren't disclosed and the deal was set to close in Q2 2026.
#Acquisition #MedTech #Cardiology
View postApril 14, 2026
Q1 2026 sales up 9.9% to $24.1 billion
Innovative Medicine brought in $15.4 billion and MedTech $8.6 billion in the first quarter. J&J raised its 2026 outlook to about $100.8 billion of sales and $11.55 adjusted EPS.
#Earnings #Growth #Guidance
View postNovember 17, 2025
J&J to acquire Halda Therapeutics for $3.05 billion
The all-cash deal added Halda's RIPTAC platform and lead oral prostate cancer candidate HLD-0915 to the oncology pipeline. J&J flagged about $0.15 per share of adjusted EPS dilution in 2026.
#Acquisition #Oncology #Pipeline
View postJoaquin Duato is Chairman and Chief Executive Officer. Joseph J. Wolk is Executive Vice President and Chief Financial Officer.
